H. pylori eradication does not reduce paraprotein levels in monoclonal gammopathy of unknown significance (MGUS): a prospective cohort study.
Monoclonal gammopathy of unknown significance (MGUS) is a chronic haematological alteration that carries a 1% risk per year of malignant evolution. The origin of this disturbance remains unknown. Previous reports have suggested that a subgroup of patients presenting MGUS might cure after Helicobacter pylori eradication. This study evaluates the effect of H. pylori eradication in a cohort of 30 patients with MGUS. A 7-day clarithromycin-based triple treatment was prescribed to patients with MGUS infected with H. pylori. Quantification of the monoclonal component was performed at inclusion and at least 12 months after treatment. The monoclonal component persisted unchanged in all patients who cured the H. pylori infection.
Soler
Juan-Alfonso
JA
Servei d'Hematologia, Hospital de Sabadell, Institut Universitari Parc Taulí, Universitat Autónoma de Barcelona, Sabadell, Barcelona, Spain. jsoler@tauli.cat
Güell
Mercé
M
Bricullé
Meritxell
M
Gavarró
Antoni
A
Roig
Imma
I
Sanchez
Jordi
J
Gisbert
Javier P
JP
García
Pilar
P
Villoria
Albert
A
Calvet
Xavier
X
D000368:Aged; D000369:Aged, 80 and over; D017291:Clarithromycin / Q000008:administration & dosage*; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008998:Monoclonal Gammopathy of Undetermined Significance / Q000188:drug therapy / Q000276:immunology* / Q000821:virology*; D010266:Paraproteins / Q000032:analysis*; D011446:Prospective Studies; D015203:Reproducibility of Results; D016896:Treatment Outcome
D010266:Paraproteins; D017291:Clarithromycin